Glucotrack Submits FDA Application to Advance Continuous Blood Glucose Monitoring Technology

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: May 14 2026

0mins

GCTK+1.54%

Explore Agentic TradingLet AI Trade for You

Source: Newsfilter

FDA Application Submitted: Glucotrack successfully submitted its Investigational Device Exemption (IDE) application to the FDA for its fully implantable Continuous Blood Glucose Monitoring (CBGM) technology, marking a key milestone towards initiating U.S. clinical trials in the second half of 2026, which is expected to propel the clinical evaluation of its technology.
Clinical Data Validation: The company published two peer-reviewed articles in the IEEE Sensors Journal and The Journal of Diabetes Research, validating the long-term stability and accuracy of its glucose sensor, with a reported 6.8% Mean Absolute Relative Difference (MARD), providing scientific evidence for the clinical application of the CBGM technology.
Financial Position Improvement: In the first quarter, the company significantly improved its financial position by reducing the outstanding balance of its $3.6 million promissory note to approximately $1.6 million, while also drawing approximately $1.0 million from its existing equity line of credit, enhancing its operational cash flow sustainability.
Increased R&D Expenses: Research and development expenses for Q1 2026 were $2.1 million, up from $1.9 million in Q1 2025, primarily due to timing changes in product and manufacturing development activities, reflecting the company's ongoing commitment to technology development.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy GCTK?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on GCTK

About GCTK

Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Glucotrack Reports Reduced Net Loss in Q1 2026

May 15 2026seekingalpha

Reduced Net Loss: In Q1 2026, Glucotrack reported a net loss of $4.3 million, a significant decrease from the $6.8 million loss in Q1 2025, indicating improvements in cost control and operational efficiency.
Cash Position: As of March 31, 2026, the company's cash and cash equivalents stood at $3.9 million, down from $7.4 million as of December 31, 2025, reflecting some pressure on the company's financial management.
Year-over-Year Comparison: While the reduction in net loss is positive, the decline in cash reserves may impact the company's short-term operational capacity, necessitating close attention to future financing strategies and cash flow management.
Strategic Reevaluation Needed: With decreasing cash flow, Glucotrack may need to reassess its business strategy to ensure sustainable growth and profitability in a competitive market environment.